TechBio 3.0 closes the drug discovery loop with multimodal AI and generative chemistry.

Artificial intelligence (AI) has transformed molecular prediction and design, yet these advances remain only partially integrated with experimental discovery. We define TechBio 3.0 as an emerging paradigm for closed-loop drug discovery that connects multimodal molecular representations, generative chemistry, and automated experimentation. We examine its early preclinical and clinical evidence, identify remaining technical and translational barriers, and argue that this convergence is beginning to define biotechnology's next era.